RapidEye Insulet ( NASDAQ: PODD ) said it has received FDA clearance for its Omnipod 5 Automated Insulin Delivery, or AID, system for the treatment of type 2 diabetes in adults. The company said the clearance makes Omnipod 5 the only AID system approved for both type 1 and type 2 diabetes management. More on Insulet Insulet Corporation 2024 Q2 - Results - Earnings Call Presentation Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023 Insulet Q2 2024 Earnings Preview Insulet's prelim Q2 revenue tops estimates.